February 16, 2017

Biosimilars in Oncology

WEB EXCLUSIVE: With the patents set to expire for a number of monoclonal antibodies, interest related to cancer biosimilars has expanded.

December 16, 2016

Legal Aspects of Biosimilars

The recent introduction of biosimilars into the U.S. market creates the need for an understanding of FDA and state regulations.

October 14, 2016

Biosimilars: Current Approvals and Pipeline Agents

To date, only four biosimilars have been approved in the U.S. (Zarxio, Inflectra, Erelzi, Amjevita), although many other agents are under development.

October 14, 2016

Will Pharmacists Fuel Biosimilars?

Pharmacists can build patient confidence about biosimilars, promoting access to more economical treatment.